Peptide documentation is strongest when it answers two separate questions: what material is present and how much of the detected material is represented by the main chromatographic peak. High-performance liquid chromatography (HPLC) and mass spectrometry (MS) are commonly used together because neither result, by itself, answers every question about a research material.
What HPLC can show
HPLC separates components in a sample and reports their relative detector response over time. A chromatogram can help show whether the sample contains one dominant peak or multiple detectable components. The reported purity percentage is generally an area-based chromatographic result under the laboratory’s stated method; it is not automatically a complete measurement of vial contents, identity, sterility, endotoxin status, or biological activity.
When reviewing an HPLC report, record the test method, detector, retention time, integration approach, sample identifier, batch or lot identifier, test date, and laboratory identity. A purity number without the underlying method and sample traceability provides much less useful evidence.
What mass spectrometry can show
Mass spectrometry measures mass-to-charge signals and can support molecular-identity assessment when the observed signal is consistent with the expected material. Interpretation depends on the instrument, ionization mode, charge state, sample preparation, and method. An expected mass signal supports identity; it does not, by itself, establish chromatographic purity, total quantity, or suitability for any particular experiment.
Why the methods are complementary
A useful documentation packet often pairs chromatographic evidence with identity evidence. Peer-reviewed recommendations for research peptides describe mass spectrometry for identity confirmation and HPLC for purity assessment, while also emphasizing that the amount supplied should be stated separately. The U.S. Food and Drug Administration’s analytical-method guidance likewise evaluates specificity, accuracy, precision, and other validation characteristics as distinct considerations.
- Identity: Does the observed analytical evidence support the expected material?
- Purity profile: What does the chromatogram show under the stated method?
- Quantity: What amount is represented, and how was it established?
- Traceability: Can the report be matched to the exact batch or lot received?
Minimum report-review checklist
- Match the product name and batch or lot identifier on the container to the report.
- Confirm the testing laboratory and report date are shown.
- Identify which method produced each result; do not treat HPLC and MS as interchangeable.
- Look for the expected-mass statement or interpretation, not only a screenshot of a spectrum.
- Review the chromatogram and stated purity result together.
- Separate purity, identity, and quantity claims in your records.
- Record any mismatch, missing page, unexplained alteration, or unclear sample identifier before use.
Important limits
Analytical documentation applies to the sample submitted and the method used. It should not be stretched into medical, therapeutic, or human-use claims. A historical or example certificate must never be presented as proof for a currently shipping lot unless the identifiers actually match.
Primary and technical references
- FDA: Q2(R1) Validation of Analytical Procedures
- PubMed: Chromatographic characterization techniques for peptide materials
- Peer-reviewed recommendations on reporting peptide identity, purity, and amount
- NIST: Organic Chemical Metrology Group
Next steps: Review our COA Library, continue through the Research Resources, or contact Transition Biotech with a documentation question.
Transition Biotech materials are sold strictly for laboratory research use only. Not for human or animal consumption, medical, diagnostic, therapeutic, cosmetic, food, supplement, or household use.
